Menu
LAUSANNE, Switzerland, 15 February 2016 – Sophia Genetics, the global leader in Data-Driven Medicine (DDM), announced today the signing of a new strategic partnership with Integrated DNA Technologies (IDT). Under the terms of the agreement, Sophia Genetics will combine its Sophia DDM™ analytics platform with IDT’s NGS target capture products. The new bundle will create the most advanced NGS data analytics platform in the market.
With these bundle solutions, Sophia Genetics will address the needs of European hospitals that are moving from small panels (1–20 genes) to medium panels (21–200 genes). The collaboration between the companies has produced a superior NGS target capture system that combines top analytical performance, high sample throughput, and flexibility.
Jurgi Camblong, CEO and founder of Sophia Genetics, commented, “The NGS bundle solutions are a true game changer for hospitals, relieving them of the burden of testing multiple NGS enrichment technologies. Having evaluated a large number of DNA enrichment technologies, we can now offer hospitals validated solutions that combine best-in-class target enrichment products with our advanced machine-learning based analytics. This will simplify validation of future NGS tests to meet hospitals’ needs for high quality diagnostics.”
Dr. Joseph A. Walder, IDT founder and CEO, commented, “We are proud of this partnership with Sophia Genetics. Sophia’s technology has triggered rapid advances in clinical genomics in recent years. With more labs and hospitals joining the clinical genomics community, we are confident Sophia Genetics is an ideal partner as we extend our target capture solutions to healthcare institutions in Europe for the ultimate benefit of patients.”
The first bundle solution to be launched will be for diagnosis of hereditary cancers, such as breast, ovarian, and colon cancers. Future solutions will target leukaemia and cardiac disease. With this partnership, Sophia Genetics and IDT are taking a pragmatic approach in helping hospitals address their need to adopt NGS tests for routine clinical diagnostics. The partnership also establishes a foundation for additional growth in this area.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
